Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,597 across all filing types
Latest filing 2015-03-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于重大资产重组进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a major asset restructuring by Guangdong Taicheng Pharmaceutical Co., Ltd. It mentions stock suspension due to the ongoing major asset reorganization, updates on due diligence, audit, and evaluation work, and the continuation of stock suspension until the board approves and announces the restructuring plan. The document is a progress update on a major asset reorganization, not the actual restructuring plan or report. It fits the category of Capital/Financing Update (CAP) as it relates to significant financing and capital structure changes due to the asset reorganization. The document length is short and focused on progress updates, not a full report or financial statements, so it is not an Annual Report or Interim Report. Therefore, the correct classification is CAP with high confidence.
2015-03-26 Chinese
关于重大资产重组进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a major asset restructuring by Guangdong Taicheng Pharmaceutical Co., Ltd. It mentions stock suspension due to the ongoing major asset reorganization, references to regulatory compliance, and periodic progress updates every five trading days. The document does not contain financial statements or detailed financial data but is an update on the status of a corporate action (major asset restructuring). This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as major asset reorganizations.
2015-03-22 Chinese
关于重大资产重组进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the progress of a major asset restructuring. It mentions stock suspension due to the planned major asset reorganization, updates on the progress including due diligence, audit, and evaluation work, and references regulatory rules about disclosure and stock suspension. The document is a progress update on a capital restructuring event, not a full financial report or final announcement. It fits the category of Capital/Financing Update (CAP) as it relates to ongoing financing and restructuring activities.
2015-03-15 Chinese
关于将部分募集资金继续转为定期存款方式存放的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the management of part of its raised funds by converting them into fixed-term deposits. It details the amounts, deposit terms, interest earned, and compliance with regulatory requirements. The document references prior announcements and audit reports but primarily focuses on the update about the use and management of raised capital funds. It does not contain financial statements, earnings data, or detailed financial analysis. The document length is 3430 characters, which is relatively short and consistent with an announcement rather than a full report. The content fits the description of a Capital/Financing Update (CAP) as it relates to the management and placement of raised capital funds.
2015-03-09 Chinese
关于重大资产重组进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the progress of a major asset restructuring. It mentions stock suspension due to the planning of a significant matter, periodic progress updates every five trading days, and ongoing work by intermediaries such as due diligence, auditing, and evaluation. The document does not contain financial statements or detailed financial data but is a progress update on a corporate restructuring event. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is short and focused on the announcement of progress rather than a full report or final decision, so it is not a full M&A filing or merger proxy statement. Therefore, the best classification is CAP with high confidence.
2015-03-08 Chinese
关于重大资产重组进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a major asset restructuring by Guangdong Taicheng Pharmaceutical Co., Ltd. It mentions stock suspension due to the ongoing major asset restructuring, references to previous announcements, and ongoing work such as due diligence, equity structure adjustment, and signing of framework agreements. The document is relatively short (972 characters) and focuses on providing updates on the progress of a major asset restructuring rather than the full details or final report of the transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including major asset restructurings. It is not a full merger or acquisition filing (MA or TAR) since it is an update on progress rather than a final merger or tender offer document. Therefore, the appropriate classification is CAP with high confidence.
2015-03-01 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.